MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers18010159

Медицинская библиотека · Cancers · 2026

15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study.

Lai Binbin, Mei Chen, Yan Xiao, Chen Lieguang, Wang Yi, Sheng Lixia, Tang Shanhao, Mao Liping, Zhang Ping, Sun Yongcheng, Xie Wanzhuo, Zhou De, Mai Wenyuan, Wang Huafeng, Ma Liya, Lou Yinjun, Wu Wenjun, Jiang Huifang, Zhang Jin, Ye Baodong, Tong Hongyan, Ouyang Guifang

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Higher-risk myelodysplastic syndromes (HR-MDS) carry a high risk of progression to acute myeloid leukemia and poor overall survival. Hypomethylating agents (HMAs), such as azacitidine, remain the standard of care but have limited efficacy. A 15-day venetoclax-azacitidine regimen has shown promising objective response rates (ORR) and potential as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) in relapsed/refractory HR-MDS. We conducted a prospective multicenter trial to evaluate its efficacy and safety in previously untreated patients.

METHODS

This multicenter prospective study enrolled treatment-naïve HR-MDS patients (IPSS-R > 3.5). Venetoclax was administered on days 1-15 (escalated from 100 to 400 mg), combined with azacitidine (75 mg/m2) on days 1-7 of each 28-day cycle. The primary endpoint was ORR (2006 IWG criteria); secondary endpoints included complete remission (CR), overall survival (OS), and AML progression.

RESULTS

Twenty-eight patients (median age: 63 years) were enrolled, with a median follow-up of 8.5 months. ORR was 85.7% per 2006 IWG (CR: 35.7%, marrow CR: 50.0%), and 78.6% per 2023 IWG (CR: 35.7%). Responses were consistent across molecular and IPSS-R subgroups. Median OS was not reached. High neutrophil count and high cytogenetic risk were favorable factors; TP53 mutation/deletion was an adverse prognostic marker. Grade 3-4 hematologic toxicities included neutropenia (96.4%), anemia (71.4%), and thrombocytopenia (64.3%). Serious adverse events (35.7%) were mainly infections. No dose-limiting or unexpected toxicities were observed.

CONCLUSIONS

The 15-day venetoclax plus azacitidine regimen demonstrated high efficacy and manageable toxicity in treatment-naïve HR-MDS. It may be particularly beneficial for patients with high neutrophil counts, adverse cytogenetics, or those eligible for HSCT, supporting further investigation in larger trials.

Для цитирования: Lai Binbin, Mei Chen, Yan Xiao, Chen Lieguang, Wang Yi, Sheng Lixia, Tang Shanhao, Mao Liping, Zhang Ping, Sun Yongcheng, Xie Wanzhuo, Zhou De, Mai Wenyuan, Wang Huafeng, Ma Liya, Lou Yinjun, Wu Wenjun, Jiang Huifang, Zhang Jin, Ye Baodong, Tong Hongyan, Ouyang Guifang. 15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study.. Cancers. 2026. DOI: 10.3390/cancers18010159.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.